SG10201908019UA - MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY - Google Patents

MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY

Info

Publication number: SG10201908019UA
Authority: SG; Singapore
Prior art keywords: modified; avidity; high affinity; specificity; growth factor
Prior art date: 2015-03-04

Application number

Other languages

English (en)

Inventor

Huawei Qiu

Julie Bird

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-03-04

Filing date

2016-03-03

Publication date

2019-10-30

2016-03-03 Application filed by Genzyme Corp filed Critical Genzyme Corp

2019-10-30 Publication of SG10201908019UA publication Critical patent/SG10201908019UA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Mycology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SG10201908019U 2015-03-04 2016-03-03 MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY SG10201908019UA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201562128149P	2015-03-04	2015-03-04

Publications (1)

Publication Number	Publication Date
SG10201908019UA true SG10201908019UA (en)	2019-10-30

Family

ID=55524479

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201707109XA SG11201707109XA (en)	2015-03-04	2016-03-03	Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity
SG10201908019U SG10201908019UA (en)	2015-03-04	2016-03-03	MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG11201707109XA SG11201707109XA (en)	2015-03-04	2016-03-03	Modified-igg antibodies that bind transforming growth factor-beta1 with high affinity, avidity and specificity

Country Status (24)

Country	Link
US (3)	US11325970B2 (pt)
EP (2)	EP3265487B1 (pt)
JP (1)	JP6745275B2 (pt)
KR (1)	KR102560072B1 (pt)
CN (1)	CN107787329B (pt)
AR (1)	AR103840A1 (pt)
AU (1)	AU2016226098B2 (pt)
BR (1)	BR112017018678A2 (pt)
CA (1)	CA2978439A1 (pt)
DK (1)	DK3265487T3 (pt)
ES (1)	ES2927297T3 (pt)
HR (1)	HRP20221142T1 (pt)
HU (1)	HUE059644T2 (pt)
IL (1)	IL254239B2 (pt)
LT (1)	LT3265487T (pt)
MX (1)	MX2017011252A (pt)
PL (1)	PL3265487T3 (pt)
PT (1)	PT3265487T (pt)
RS (1)	RS63589B1 (pt)
RU (1)	RU2728858C2 (pt)
SG (2)	SG11201707109XA (pt)
SI (1)	SI3265487T1 (pt)
TW (1)	TWI733661B (pt)
WO (1)	WO2016141245A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI733661B (zh)	2015-03-04	2021-07-21	美商健臻公司	以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh)	2015-03-04	2021-05-11	美商健臻公司	具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
KR20180122397A (ko)	2016-03-11	2018-11-12	스칼러 락, 인크.	TGFβ1-결합 이뮤노글로불린 및 그의 용도
US11326182B2 (en)	2016-04-29	2022-05-10	Voyager Therapeutics, Inc.	Compositions for the treatment of disease
US11299751B2 (en)	2016-04-29	2022-04-12	Voyager Therapeutics, Inc.	Compositions for the treatment of disease
TW202313678A (zh) *	2017-01-20	2023-04-01	法商賽諾菲公司	抗TGF-β抗體及其用途
CA3104274A1 (en)	2018-05-10	2019-11-14	Mirabiologics Inc.	Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides
US20220119513A1 (en) *	2020-06-08	2022-04-21	Zoetis Services Llc	Anti-tgfb antibodies and therapeutic uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020099179A1 (en)	1989-12-21	2002-07-25	Linda K. Jolliffe	Cdr-grafted antibodies
US5616561A (en)	1995-03-31	1997-04-01	Regents Of The University Of California	TGF-β antagonists as mitigators of radiation-induced tissue damage
EP1486560A3 (en)	1999-04-30	2005-02-09	Cambridge Antibody Technology LTD	Specific antibodies and antibody fragments for TGFBETA1
US6492497B1 (en) *	1999-04-30	2002-12-10	Cambridge Antibody Technology Limited	Specific binding members for TGFbeta1
US20060286105A1 (en)	2003-04-30	2006-12-21	Steven Ledbetter	Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
MXPA06011199A (es)	2004-03-31	2007-04-16	Genentech Inc	Anticuerpos anti-tgf-beta humanizados.
WO2006036729A2 (en)	2004-09-22	2006-04-06	Genzyme Corporation	USE OF TGF-β ANTAGONISTS TO LIMIT NEPHROTOXICITY OF IMMUNOSUPPRESSIVE AGENTS
US9284375B2 (en)	2005-04-15	2016-03-15	Macrogenics, Inc.	Covalent diabodies and uses thereof
CA2607448C (en)	2005-04-22	2014-11-18	Eli Lilly And Company	Tgf beta 1 specific antibodies
ATE545657T1 (de)	2005-12-23	2012-03-15	Lilly Co Eli	Tgf-beta antikörper
JP5374359B2 (ja)	2006-03-17	2013-12-25	バイオジェン・アイデック・エムエイ・インコーポレイテッド	安定化されたポリペプチド化合物
EP2006380A4 (en)	2006-03-23	2010-08-11	Kyowa Hakko Kirin Co Ltd	AGONIST ANTIBODY AGAINST THE HUMAN THROMBOPOIETINE RECEPTOR
MX2009003518A (es) *	2006-10-03	2009-08-25	Genzyme Corp	Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
AU2009266856A1 (en)	2008-07-02	2010-01-07	Emergent Product Development Seattle, Llc	IL6 immunotherapeutics
EP2655624B1 (en)	2010-12-23	2017-11-29	Biogen MA Inc.	Linker peptides and polypeptides comprising same
TWI803876B (zh)	2011-03-28	2023-06-01	法商賽諾菲公司	具有交叉結合區定向之雙重可變區類抗體結合蛋白
PT2714735T (pt)	2011-06-03	2021-10-26	Xoma Technology Ltd	Anticorpos específicos para tgf-beta
JP2015531751A (ja)	2012-07-23	2015-11-05	ザイムワークス，インコーポレイテッド	選択的対である軽鎖および重鎖を含む免疫グロブリン構築物
EP2971048B1 (en)	2013-03-11	2018-10-31	Genzyme Corporation	Engineered anti-tgf-beta antibodies and antigen-binding fragments
TWI733661B (zh)	2015-03-04	2021-07-21	美商健臻公司	以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh)	2015-03-04	2021-05-11	美商健臻公司	具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體

2016
- 2016-03-02 TW TW105106247A patent/TWI733661B/zh active
- 2016-03-03 DK DK16709666.8T patent/DK3265487T3/da active
- 2016-03-03 AU AU2016226098A patent/AU2016226098B2/en active Active
- 2016-03-03 RU RU2017134043A patent/RU2728858C2/ru active
- 2016-03-03 LT LTEPPCT/US2016/020780T patent/LT3265487T/lt unknown
- 2016-03-03 WO PCT/US2016/020780 patent/WO2016141245A1/en active Application Filing
- 2016-03-03 EP EP16709666.8A patent/EP3265487B1/en active Active
- 2016-03-03 ES ES16709666T patent/ES2927297T3/es active Active
- 2016-03-03 US US15/555,500 patent/US11325970B2/en active Active
- 2016-03-03 BR BR112017018678A patent/BR112017018678A2/pt active Search and Examination
- 2016-03-03 AR ARP160100560A patent/AR103840A1/es unknown
- 2016-03-03 CA CA2978439A patent/CA2978439A1/en active Pending
- 2016-03-03 MX MX2017011252A patent/MX2017011252A/es unknown
- 2016-03-03 SI SI201631598T patent/SI3265487T1/sl unknown
- 2016-03-03 PT PT167096668T patent/PT3265487T/pt unknown
- 2016-03-03 CN CN201680025633.5A patent/CN107787329B/zh active Active
- 2016-03-03 RS RS20220886A patent/RS63589B1/sr unknown
- 2016-03-03 KR KR1020177027372A patent/KR102560072B1/ko active IP Right Grant
- 2016-03-03 SG SG11201707109XA patent/SG11201707109XA/en unknown
- 2016-03-03 HU HUE16709666A patent/HUE059644T2/hu unknown
- 2016-03-03 SG SG10201908019U patent/SG10201908019UA/en unknown
- 2016-03-03 EP EP22180865.2A patent/EP4163299A1/en active Pending
- 2016-03-03 PL PL16709666.8T patent/PL3265487T3/pl unknown
- 2016-03-03 JP JP2017546179A patent/JP6745275B2/ja active Active
- 2016-03-03 HR HRP20221142TT patent/HRP20221142T1/hr unknown
2017
- 2017-08-31 IL IL254239A patent/IL254239B2/en unknown
2022
- 2022-04-11 US US17/717,967 patent/US11834495B2/en active Active
2023
- 2023-10-23 US US18/492,150 patent/US20240117028A1/en active Pending

Also Published As

Publication number	Publication date
RU2017134043A3 (pt)	2019-08-29
HUE059644T2 (hu)	2022-12-28
ES2927297T3 (es)	2022-11-04
JP6745275B2 (ja)	2020-08-26
RU2017134043A (ru)	2019-04-05
AR103840A1 (es)	2017-06-07
CN107787329A (zh)	2018-03-09
AU2016226098A1 (en)	2017-10-26
SG11201707109XA (en)	2017-09-28
SI3265487T1 (sl)	2022-10-28
CA2978439A1 (en)	2016-09-09
RS63589B1 (sr)	2022-10-31
PL3265487T3 (pl)	2023-01-23
IL254239A0 (en)	2017-10-31
EP4163299A1 (en)	2023-04-12
KR20170120689A (ko)	2017-10-31
DK3265487T3 (da)	2022-09-26
MX2017011252A (es)	2018-02-19
EP3265487A1 (en)	2018-01-10
IL254239B2 (en)	2023-06-01
US20220315649A1 (en)	2022-10-06
US20240117028A1 (en)	2024-04-11
US20180044412A1 (en)	2018-02-15
TWI733661B (zh)	2021-07-21
RU2728858C2 (ru)	2020-07-31
CN107787329B (zh)	2021-08-24
AU2016226098B2 (en)	2021-11-25
US11834495B2 (en)	2023-12-05
KR102560072B1 (ko)	2023-07-25
HRP20221142T1 (hr)	2022-11-25
WO2016141245A1 (en)	2016-09-09
EP3265487B1 (en)	2022-06-29
US11325970B2 (en)	2022-05-10
TW201706306A (zh)	2017-02-16
JP2018512124A (ja)	2018-05-17
LT3265487T (lt)	2022-09-26
PT3265487T (pt)	2022-09-29
BR112017018678A2 (pt)	2018-04-17
KR20230116946A (ko)	2023-08-04

Publication	Publication Date	Title
SG10201908019UA (en)	2019-10-30	MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY
PH12020551491A1 (en)	2021-09-06	USE OF ANTI-HUMAN SIRPA Vl ANTIBODIES AND METHOD FOR PRODUCING ANTI-SIRPA Vl ANTIBODIES
PH12020550408A1 (en)	2021-04-12	Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
PH12018502623A1 (en)	2019-10-07	Anti-pd-l1 antibodies and uses thereof
PH12019502785A1 (en)	2020-09-14	Anti trbc1 antigen binding domains
NZ602320A (en)	2013-06-28	Bispecific, bivalent anti-vegf/anti-ang-2 antibodies
EP4248996A3 (en)	2023-11-08	Anti-trem2 antibodies and methods of use thereof
MA39266A (fr)	2016-02-10	Anticorps bispécifiques anti cd3epsilon et bcma
MX2014004521A (es)	2014-05-28	Anticuerpo estable de union a antigenos multiples.
MX2016015389A (es)	2017-04-13	Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo.
NZ628528A (en)	2016-07-29	Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2017152102A3 (en)	2017-10-19	Anti-trem1 antibodies and methods of use thereof
PH12020551173A1 (en)	2021-05-31	Anti-pd-l1 antibodies and uses thereof
MX2016004928A (es)	2016-07-11	Secuencias de anticuerpos con reaccion cruzada para staphylococcus aureus.
EA201791270A1 (ru)	2017-12-29	Модифицированные april-связывающие антитела
AU2012307816A8 (en)	2014-06-19	Anti-alphabeta TCR antibody
NZ586357A (en)	2012-10-26	Antibodies to the pcrv antigen of pseudomonas aeruginosa
WO2019094595A3 (en)	2020-04-02	Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
NZ594682A (en)	2013-06-28	Fully human antibodies specific to cadm1
EA201691782A1 (ru)	2017-01-30	Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
JOP20190246A1 (ar)	2019-10-16	جسم مضاد أحادي النسيلة لـ pd-l1
MX2022007231A (es)	2022-07-12	Anticuerpos anti-mertk y metodos de uso de los mismos.
MX2022007456A (es)	2022-06-27	Dimeros scfv-fc que se unen al factor de crecimiento transformante-?1 con alta afinidad, avidez y especificidad.
CL2016001028A1 (es)	2016-12-16	Anticuerpos de alta afinidad y de agregación estable basados en dominios variables de vl y derivados de vhh.
WO2016127104A3 (en)	2016-10-27	Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection